{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-257205","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.713010+00:00","generated_at":"2026-05-30T01:03:05.910864+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Taysha Q3 net loss $25.5M; TSHA-102 high dose safe; FDA aligns on pivotal trial design","bullets":["Net loss $25.5M ($0.10/sh) vs $117.1M loss in Q3 2023; cash $157.7M into Q4 2026.","High dose TSHA-102 well tolerated; no SAEs or DLTs in 2 adolescent/adult and 1 pediatric patient.","FDA aligned on trial design, endpoints, and natural history dataset for Part B of REVEAL trials.","FDA approved pivotal TSHA-102 product manufactured with final commercial manufacturing process for REVEAL trials.","Safety and efficacy data from high dose cohorts of both REVEAL trials expected H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-257205","json":"https://secwatch.observer/filing/0001193125-24-257205.json","markdown":"https://secwatch.observer/filing/0001193125-24-257205.md","text":"https://secwatch.observer/filing/0001193125-24-257205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312524257205/0001193125-24-257205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312524257205/d877348d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:03:05.910864+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}